2026 MSK Cardio-Oncology Symposium — On Demand

The rapid growth of cancer therapeutics has improved outcomes and survival for many patients while introducing new and significant cardiovascular risks, underscoring the importance of cardio-oncology at the critical intersection of cancer and heart health. This on demand program offers a comprehensive, case-based curriculum that highlights the latest advances in cancer care alongside evidence-based strategies for the prevention, early detection, and management of cardiovascular disease in patients with cancer.

Designed for clinicians, researchers, and trainees, this program offers participants an opportunity to review cutting-edge science, learn best practices, and gain insights from leaders in the growing global cardio-oncology community. 

Course content features expert-led presentations, recorded Q&A sessions, and case-based discussions. Registration options include the Full Course, which provides access to all sessions listed below, or the option to select individual sessions.

• Session I (Immunotherapy)

  • Fundamentals of Antitumor Immunity and Current Applications in Solid Tumors - James W. Smithy, MD, MHS

  • Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Current Approaches and New Frontiers - Alexander Lyon, MA, BM, BCh, PhD

  • Q&A and Discussion

• Session II (Lung Cancer and Genitourinary Cancer)

  • Updates on Contemporary Lung Cancer Diagnosis and Treatment: A Primer for the Non-Oncologist - Helena A. Yu, MD

  • Cardiovascular Considerations Associated with Lung Cancer Treatment: Screening, Diagnosis, and Management - Anthony F. Yu, MD, MS

  • Q&A and Discussion

  • Contemporary Management of Prostate Cancer: Hormonal Therapy, Radiation and Surgery — What Factors Influence Treatment Decisions? - Karen A. Autio, MD, MSc

  • Cardiovascular Considerations in GU Cancer Therapy: Screening and Managing Treatment-related Cardiotoxicity - Krishan Sharma, MD

  • Q&A and Discussion

• Session III (Breast Cancer) and Special Lecture

  • Contemporary Breast Cancer Treatment: From Anti-HER2 Therapy to Beyond - Chau T. Dang, MD

  • Cardiovascular Toxicities in Modern Breast Cancer Therapy: Updates on Screening and Management - Anthony F. Yu, MD, MS

  • How to Train in Cardio-Oncology: Cardio-Oncology Fellowship Programs - Dipti Gupta, MD, MPH

  • Q&A and Discussion

• Session IV (CV Considerations in Hematologic Malignancies)

  • Understanding Stem Cell/Bone Marrow Transplant — When, for Whom and Why? - Brian C. Shaffer, MD, MS

  • Cardiovascular Challenges During and After Bone Marrow Transplant: Mitigating Risk and Optimizing CV Health - Daniel Addison, MD

  • Advances in T-Cell Therapies for Hematologic Cancers: CAR T, Bispecific Antibodies, and Beyond - Miguel-Angel Perales, MD

  • T-Cell Immunotherapies and the Heart: Risks, Detection, and Management - Eric H. Yang, MD

  • Q&A and Discussion

• Session V (Amyloidosis and Multiple Myeloma)

  • Multiple Myeloma and AL Amyloidosis: A Primer on Diagnosis and Management - Heather J. Landau, MD

  • Cardiac Amyloidosis: Unmasking the Great Masquerader — When to Suspect, How to Diagnose - Richard K. Cheng, MD, MSc

  • Managing Patients with TTR Amyloidosis: Progress and Challenges - Daniel McDonald, MD

  • Q&A and Discussion

• Session VI (Thrombosis and Hemostasis) + ICOS special lecture

  • Venous Thromboembolism in Cancer Patients: Risk Assessment, Prevention and Treatment - Jeffrey Zwicker, MD

  • Cancer-Associated Stroke: Etiology, Detection, and Management - Babak Navi, MD

  • International Cardio-Oncology Society: Opportunities for Collaboration, Research, and Education - Michael G. Fradley, MD

• Session VII (Opening Lecture (Liu), Keynote lecture (Armenian), A Decade in Review (Lyon))

  • Setting the Stage: The Evolving Landscape of Cardio-Oncology - Jennifer Liu, MD

  • Laying the Foundation for Precision Cardio-Oncology: Defining Risk, Outcomes, and Surveillance - Saro H. Armenian, DO, MPH

  • A Decade in Review: Top Research Studies and Clinical Trials in Cardio-Oncology - Alexander Lyon, MA, BM, BCh, PhD

• Session VIII (Role of Imaging)

  • Precision Imaging in Cardio-Oncology: Leveraging Echo and CMR for Risk Stratification and Early Detection - Paaladinesh Thavendiranathan, MD, MSc

  • Biomarkers in Risk Prediction and Diagnosis - Joshua D. Mitchell, MD

  • MR Imaging of Cardiac Masses: Clinical Applications and Prognostic Implications - Jonathan W. Weinsaft, MD

  • Q&A and Discussion

• Session IX (Electrophysiology and Radiation)

  • Atrial Fibrillation and Cancer: Pathophysiology and Management Algorithm -Michael G. Fradley, MD

  • Management of Cardiac Implantable Devices During Radiation, MRI, and Emerging Treatment Modalities - Michael G. Fradley, MD

  • Q&A and Discussion

  • Radiation Induced Heart Disease: A Practical Guide to Diagnosis and Management - Joshua D. Mitchell, MD

  • Radiation Therapy: Current and Future Strategies to Minimize Radiation Induced Cardiotoxicity - Lior Z. Braunstein, MD

  • Q&A and Discussion

• Session X (Survivorship)

  • Late Onset Cardiotoxicity in Adult Survivors of Childhood Cancer: Incidence, Risk Factors, and Individual CV Risk Prediction - Anju Nohria, MD, MSc

  • Clonal Hematopoiesis: Redefining Cardiovascular Risk in Oncology and Beyond - Saro H. Armenian, DO, MPH

  • Pharmacologic Cardioprotection in Oncology: GDMT and Beyond? - Anita Deswal, MD, MPH, MBBS

  • Exercise as Cardioprotection in Oncology: From Evidence to Clinical Practice - Jessica Scott, PhD

  • Cardio-Oncology Care and Health Equity: Challenges and Opportunities - Michelle N. Johnson, MD, MPH

  • Q&A and Discussion

• Session XI (Best Practices)

  • 2022 ESC Cardio-Oncology Guidelines: Where We Go From Here - Teresa López-Fernández, MD

  • Advanced HF Management in Cardio-Oncology - Jayant K. Raikhelkar, MD

  • 5FU Induced Chest Pain: Diagnostic and Management Algorithm - Stephanie Feldman, MD

  • Navigating Cardiac Interventions in Patients with Active Cancer: Insights from Evidence and Experience - Dmitriy N. Feldman, MD

  • Q&A and Discussion

• Session XII (Case Discussions)

  • The Spectrum of ICI Myocarditis: Clinical Lessons from Mild to Fulminant Presentations Presenter: Marie-Claude Beaulieu, MD; Discussant: Carol L. Chen, MD

  • Clinical Case Management in Cardio-Oncology: Emerging Approaches and Evolving Practice

    • CASE 1 Dexrazoxane for Cardioprotection - Anthony F. Yu, MD, MS

    • CASE 2 Permissive Cardiotoxicity - Jennifer Liu, MD

    • CASE 3 Role of Second-Line Immunosuppressants in ICI Myocarditis: When and for Whom? - Dipti Gupta, MD, MPH

    • Q&A and Discussion

This program is intended for cardiologists, internists, hematologists/oncologists, advanced practice providers, nurses, and other allied healthcare professionals who care for patients with cancer or are interested in the evolving field of cardio-oncology. 

1. Describe contemporary anti-cancer therapies—including anthracyclines, targeted agents, immune checkpoint inhibitors, CAR-T and other cellular therapies, and hormonal therapies—highlighting their mechanisms of action and roles in cancer treatment.
2. Outline the cardiotoxicity profiles of these therapies and explain their impact on the cardiovascular system.
3. Apply principles of cardiovascular risk stratification based on patient- and treatment-specific factors to guide surveillance and management.
4. Determine strategies for monitoring and managing cardiotoxicity, recognizing both the supporting evidence and the current gaps in knowledge.
5. Explain diagnostic and therapeutic approaches to cardiac amyloidosis, including recent advances in disease-modifying treatments.
6. Demonstrate the principles of permissive cardiotoxicity and apply them to specific clinical scenarios.
7. Summarize the role and optimal use of cardiovascular imaging modalities in contemporary cardio-oncology, guided by current guidelines and best practices.
8. State the late cardiovascular sequelae of cancer treatment and outline best practices for managing the cardiovascular health of adult survivors of childhood and adolescent cancers.
9. Illustrate the unique challenges and strategies for managing acute cardiovascular disease in patients actively undergoing cancer therapy.

Registration options include the Full Course, which provides access to all sessions listed above, or the option to select individual sessions. To enroll, please click the Register tab at the top of the page. Once registered, all materials, including instructions for claiming credit, are located under the Course Content tab above.

For those that purchase this on demand, access to the content and the opportunity to claim credit will be available through December 31, 2027.

On Demand Access Fees

• Full Course

  • Physicians (MDs, PhDs, DOs): $600

  • Advanced Practice Providers: $450

  • Nurses and Other Healthcare Professionals: $400

  • Residents and Fellows: $200

  • MSK Employees: Complimentary 

• Individual Sessions (per session)

  • Physicians (MDs, PhDs, DOs): $100

  • Advanced Practice Providers: $75

  • Nurses and Other Healthcare Professionals: $65

  • Residents and Fellows: $35

  • MSK Employees: Complimentary 

Discounted registration is available for specific groups, including complimentary registration for health professional students and registrants who reside in low and lower-middle income countries. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable. For details please review our Cancellation Policy.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 14.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM credit.

MSK Symposium Directors 

Jennifer Liu, MD
Chief, Cardiology Service
Professor of Clinical Medicine, Weill Cornell Medical College

Anthony F. Yu, MD, MS
Associate Attending, Cardiology Service 
Associate Professor of Medicine, Weill Cornell Medical College 

Symposium Planning Committee 

Carol L. Chen, MD
Vice Chair, Quality Assurance
Attending, Cardiology Service
Memorial Sloan Kettering Cancer Center 

Stephanie Feldman, MD
Assistant Professor of Medicine, Division of Cardiology, Weill Cornell Medical College
Attending, New York Presbyterian-Weill Cornell Medical Center

Marie-Claude Beaulieu, MD
Cardio-oncology Fellow
Memorial Sloan Kettering Cancer Center 

Stephen Wisely, PA-C
Advanced Practice Provider 
Memorial Sloan Kettering Cancer Center

Abstract Review Committee 

Sarah Linhares, DNP
Memorial Sloan Kettering Cancer Center 

John Mancini, MD
Weill Cornell Medicine

Joseph Wallins, MD
Weill Cornell Medicine

Keynote Speaker

Saro H. Armenian, DO, MPH
Barron Hilton Chair in Pediatrics
Chair and Professor, Department of Pediatrics
Director and Professor, Division of Outcomes Research/Intervention, Department of Population Sciences
Director, Center for Survivorship and Outcomes, Hematologic Malignancies Research Institute
Director, Childhood, Adolescent and Young Adult Survivorship Program
City of Hope® Cancer Center Duarte

Guest Faculty 

Daniel Addison, MD
Director of Translational Research, Division of Cardiology
Associate Professor of Internal Medicine
UT Southwestern Medical Center
Associate Director for Survivorship and Outcomes Research
Harold C. Simmons Comprehensive Cancer Center

Richard K. Cheng, MD, MSc
Professor of Cardiology
Section Head, Heart Failure, Mechanical Circulatory Support, Heart Transplant, and Cardio-Oncology
Program Director, Advanced Heart Failure and Transplant Cardiology
University of Washington Medical Center

Anita Deswal, MD, MPH, MBBS
Chair, Department of Cardiology
Ting Tsung and Wei Fong Chao Distinguished Chair
Professor of Medicine (Term-Tenure)
The University of Texas MD Anderson Cancer Center

Dmitriy N. Feldman, MD
Director, Endovascular Service
Interventional Cardiac and Endovascular Laboratory
NewYork-Presbyterian/Weill Cornell Medical Center

Michael G. Fradley, MD
Section Chief, Consultative Cardiology
Medical Director, Thalheimer Center for Cardio-Oncology
Associate Professor of Clinical Medicine (Cardiovascular Medicine)
Penn Medicine

Teresa López-Fernández, MD
Senior Consultant Cardiologist
La Paz University Hospital

Alexander Lyon, MA, BM, BCh, PhD
Consultant Cardiologist
Clinical Lead, Cardio-Oncology Service
Royal Brompton Hospital

Daniel Matthew McDonald, MD
Assistant Attending Physician
NewYork-Presbyterian Hospital
Assistant Professor of Medicine
Weill Cornell Medical College, Cornell University

Joshua D. Mitchell, MD, MSCI
Associate Professor of Medicine
Director, Cardio-Oncology Center of Excellence
Director, Cardio-Oncology Fellowship
Co-Director, Amyloid Center of Excellence
Washington University School of Medicine

Babak Navi, MD
Vice Chair, Neurology Hospital Services
Chief, Division of Stroke and Hospital Neurology
NewYork-Presbyterian Hospital
Medical Director, Weill Cornell Stroke Center
Associate Professor of Neurology and Neuroscience
Weill Cornell Medical College

Anju Nohria, MD, MSc
Director, Cardio-Oncology Program
Dana-Farber Brigham Cancer Center
Cardiovascular Medicine Specialist
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School

Jayant K. Raikhelkar, MD
Assistant Professor of Medicine
Advanced Heart Failure and Cardiac Transplantation
Columbia University Irving Medical Center

Paaladinesh Thavendiranathan, MD, MSc
Professor of Medicine, Cardiology
Peter Munk Cardiac Centre, Toronto General Hospital
University Health Network
University of Toronto

Jonathan W. Weinsaft, MD
Chief, Division of Cardiology
NewYork-Presbyterian Hospital
Professor of Medicine
Weill Cornell Medical College

Eric H. Yang, MD
Clinical Professor of Medicine
Ronald Reagan UCLA Medical Center

MSK Faculty 

Karen A. Autio, MD, MSc
Assistant Attending, Genitourinary Oncology Service

Lior Z. Braunstein, MD
Associate Attending, External Beam Radiotherapy Service

Angel T. Chan, MD, PhD
Assistant Attending, Cardiology Service 

Chau T. Dang, MD
Attending, Breast Medicine Service 

Dipti Gupta, MD, MPH
Associate Attending, Cardiology Service 
Program Director, Cardio-Oncology Clinical Research Fellowship

Michelle N. Johnson, MD, MPH
Attending, Cardiology Service 
Vice Chair of Health Equity, Department of Medicine

Heather J. Landau, MD
Director, Amyloidosis Program
Associate Attending, Bone Marrow Transplant Service 

Eileen P. McAleer, MD
Attending, Cardiology Service 

Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplant Service

Jessica Scott, PhD
Head, Exercise Oncology Program and Principal Investigator

Brian C. Shaffer, MD, MS
Associate Attending, Bone Marrow Transplant Service
Program Director, Bone Marrow Transplantation and Immunotherapy Fellowship Programs

Krishan Sharma, MD
Assistant Attending, Cardiology Service

James W. Smithy, MD, MHS
Assistant Attending, Melanoma Service 

Helena A. Yu, MD
Attending, Thoracic Oncology Service 

Jeffrey Zwicker, MD
Chief, Hematology Service

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.